The PDE4 inhibitor tanimilast shows distinct immunomodulatory properties associated with a type 2 endotype and CD141 upregulation

Abstract Background Tanimilast is a novel and selective inhaled inhibitor of phosphodiesterase-4 in advanced clinical development for chronic obstructive pulmonary disease (COPD). Tanimilast is known to exert prominent anti-inflammatory activity when tested in preclinical experimental models as well...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Hoang Oanh Nguyen, Valentina Salvi, Laura Tiberio, Fabrizio Facchinetti, Mirco Govoni, Gino Villetti, Maurizio Civelli, Ilaria Barbazza, Carolina Gaudenzi, Mauro Passari, Tiziana Schioppa, Francesca Sozio, Annalisa Del Prete, Silvano Sozzani, Daniela Bosisio
Formato: Artigo
Idioma:Inglês
Publicado em: BMC 2022-05-01
Colecção:Journal of Translational Medicine
Assuntos:
CD141
Thrombomodulin
BDCA-3
cAMP
IL-13
Type 2 responses
Acesso em linha:https://doi.org/10.1186/s12967-022-03402-x
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados